Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 07:30 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Safety and Efficacy of Abatacept for Treating Chronic Cytopenia in Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Haploinsufficiency
NCT03733067 · National Institute of Allergy and Infectious Diseases (NIAID) · PHASE1/PHASE2 · withdrawn · last registry update 2023-12-04 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “No enrollment” | – | Registry record, National Institute of Allergy and Infectious Diseases (NIAID) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD86 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-10-23Phase 3 first posted: Duke University, TNFi (Tumor Necrosis Factor inhibitor) medication + Abatacept (NCT06654882)
- 2024-10-15Results posted on the registry: Bristol-Myers Squibb, Abatacept + Adalimumab (NCT04909801)
- 2024-10-09Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), lulizumab pegol + antithymocyte globulin (rabbit) (NCT04066114)
- 2024-10-02Results posted on the registry: Dimitrios Tzachanis, MD PhD, Cyclophosphamide + abatacept (NCT03680092)
- 2024-07-30Results posted on the registry: University of Washington, Abatacept (NCT03882008)
- 2024-06-26Phase 3 first posted: Federal Research Institute of Pediatric Hematology, Oncology and Immunology, Baricitinib (NCT06475820)
- 2024-06-06Results posted on the registry: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), CTLA4-Ig (Abatacept) + Placebo (NCT01773707)
- 2024-05-16Results posted on the registry: Roswell Park Cancer Institute, Abatacept + Dexamethasone (NCT03457142)
- 2024-03-04Phase 3 first posted: University Hospital, Rouen, Conversion to Belatacep + Standard of care treatment (SOC regimen) with Tacrolimus (NCT06291103)
- 2024-01-16Results posted on the registry: Bristol-Myers Squibb, branebrutinib + abatacept (NCT04186871)
- 2023-12-04Results posted on the registry: Massachusetts General Hospital, Immunosuppression reduction (NCT04177095)
- 2023-11-08Results posted on the registry: NYU Langone Health, Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention (NCT04503616)
- 2023-10-10Results posted on the registry: Amgen, Belatacept + VIB4920 (NCT04046549)
- 2023-05-08Results posted on the registry: Columbia University, Abatacept + Adalimumab (NCT03619876)
- 2023-05-08Also stopped (terminated): Columbia University, Abatacept + Adalimumab (NCT03619876)
- 2023-04-21Results posted on the registry: Daniel Benjamin, Infliximab + Abatacept (NCT04593940)
- 2023-02-06Results posted on the registry: NYU Langone Health, Abatacept + DMARDs (NCT03652961)
- 2022-12-13Results posted on the registry: University of California, Los Angeles, Belatacept (NCT01953120)
- 2022-12-06Also stopped (withdrawn): University of California, San Francisco, Belatacept (NCT02939365)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision